Indaptus Therapeutics is trading 8.07% up at $3.08 in after-hours, with no clear company-specific catalyst identified. - The September 29 regular-session close was $2.85, down 13.37%. - The recently announced $24 million private placement is prior context, not a confirmed reason for the move. - Major indexes were mixed; the supplied market data does not establish a broad-market explanation.